In NSCLC patients treated with paclitaxel/carboplatin/bevacizumab, proliferating peripheral blood CD8+ T cells express a higher level of PD-1 and CTLA-4 compared to non-proliferating CD8+ T cells [110]. Here, CD8A is linked to non-small cell lung carcinoma.